Search Results - "Almotlak, H"

Impact of everolimus blood concentration on its anti-cancer activity in patients with metastatic renal cell carcinoma by Thiery-Vuillemin, A., Mouillet, G., Nguyen Tan Hon, T., Montcuquet, P., Maurina, T., Almotlak, H., Stein, U., Montange, D., Foubert, A., Nerich, V., Pivot, X., Royer, B.

“…Purpose Everolimus has demonstrated its efficacy in metastatic renal cell carcinoma (mRCC). Preliminary studies have shown high variability of everolimus blood…”
Get full text

The level of circulating NKp46+ CD56dim CD16+ natural killer cells predicts distinct survival in non-small cell lung cancer by Picard, E., Godet, Y., Laheurte, C., Boullerot, L., Lauret Marie Joseph, E., Jacquin, M., Kaulek, V., Eberst, G., Gaugler, B., Jacoulet, P., Gainet-Brun, M., Lahoucarde, J., Almotlak, H., Le Pimpec-Barthes, F., Fabre-Guillevin, E., Borg, C., Westeel, V., Adotevi, O.

Get full text

5059 POSTER Systemic High-dose Intravenous Methotrexate for Central Nervous System Metastases in Breast Cancer by Bazan, F, Chaigneau, L, Villanueva, C, Thiery-Vuillemin, A, Dobi, E, Kaibacher, E, Royer, B, Curtit, E, Almotlak, H, Pivot, X

Get full text

1404P Clinical characteristics and therapeutics sequences of KRAS G12C metastatic non-small cell lung cancer (mNCSLC) patients treated by sotorasib in the French pre-marketing authorization (MA) early access program (cohort temporary authorization of use, cATU) by Lena, H., Cadranel, J., Girard, N., Mazieres, J., Curcio, H., Gille, R., Madroszyk Flandin, A-C., Auliac, J.B., Bylicki, O., Rieux, C., Couraud, S., Barlesi, F., Pichon, E., Métivier, A-C., Almotlak, H., Pabst, L., Deldycke, C., Duchemann, B., De Gunten, L., Quantin, X.

Get full text

509TiP REPROGRAM-01, a phase II study of regorafenib in combination with a multimodal metronomic chemotherapy in patients with metastatic colorectal cancer by Klajer, E., Jary, M., Borg, C., Kim, S., Vernerey, D., Henriques, J., N'Guyen, T., Nasri, M., Almotlak, H., Babre, J., Meurisse, A., Fratte, S., Fein, F., Calcagno, F., Chanut, L., Spehner, L., Rebucci-Peixoto, M., Vienot, A.

Get full text

Physicians’ satisfaction with health-related quality of life (HRQoL) assessment in daily clinical practice using electronic patient-reported outcome (ePRO) for cancer patients by Mouillet, G., Fritzsch, J., Thiery-Vuillemin, A., Meneveau, N., Almotlak, H., Mansi, L., Curtit, E., Kim, S., Jary, M., Maurina, T., Eberst, G., Barthelemy, P., Eymard, J.-C., Geoffrois, L., Djoumakh, O., Anota, A., Adotevi, O., Westeel, V., Paget-Bailly, S.

Get full text

1789PPhysicians’ satisfaction with health-related quality of life (HRQoL) assessment in daily clinical practice using electronic patient-reported outcome (ePRO) for cancer patients by Mouillet, G, Fritzsch, J, Thiery-Vuillemin, A, Meneveau, N, Almotlak, H, Mansi, L, Curtit, E, Kim, S, Jary, M, Maurina, T, Eberst, G, Barthelemy, P, Eymard, J-C, Geoffrois, L, Djoumakh, O, Anota, A, Adotevi, O, Westeel, V, Paget-Bailly, S

“…Abstract Background Routine Electronic Monitoring of HRQoL (REMOQOL) in daily clinical care with real-time feedback to physicians could help to manage…”
Get full text

1789P - Physicians’ satisfaction with health-related quality of life (HRQoL) assessment in daily clinical practice using electronic patient-reported outcome (ePRO) for cancer patients by Mouillet, G., Fritzsch, J., Thiery-Vuillemin, A., Meneveau, N., Almotlak, H., Mansi, L., Curtit, E., Kim, S., Jary, M., Maurina, T., Eberst, G., Barthelemy, P., Eymard, J.-C., Geoffrois, L., Djoumakh, O., Anota, A., Adotevi, O., Westeel, V., Paget-Bailly, S.

“…Routine Electronic Monitoring of HRQoL (REMOQOL) in daily clinical care with real-time feedback to physicians could help to manage treatment-related…”
Get full text

Updated data of epitopes-HPV02 trial and external validation of efficacy of DCF in prospective epitopes-HPV01 study in advanced anal squamous cell carcinoma. Pooled analysis of 115 patients by Kim, S., Meurisse, A., Stouvenot, M., Jary, M., Hon, T Nguyen Tan, Francois, E., Buecher, B., Andre, T., Samalin, E., Boulbair, F., De Bari, B., Almotlak, H., Klajer, E., Calcagno, F., Chatillon, E., Spehner, L., Jacquin, M., Vendrely, V., Vernerey, D., Borg, C.

Get full text

534P - Updated data of epitopes-HPV02 trial and external validation of efficacy of DCF in prospective epitopes-HPV01 study in advanced anal squamous cell carcinoma. Pooled analysis of 115 patients by Kim, S., Meurisse, A., Stouvenot, M., Jary, M., Hon, T Nguyen Tan, Francois, E., Buecher, B., Andre, T., Samalin, E., Boulbair, F., De Bari, B., Almotlak, H., Klajer, E., Calcagno, F., Chatillon, E., Spehner, L., Jacquin, M., Vendrely, V., Vernerey, D., Borg, C.

“…The addition of docetaxel to cisplatin and 5FU (DCF) has shown a promising efficacy in Epitopes-HPV01 study with 4 of first 8 consecutive patients presenting a…”
Get full text

534PUpdated data of epitopes-HPV02 trial and external validation of efficacy of DCF in prospective epitopes-HPV01 study in advanced anal squamous cell carcinoma. Pooled analysis of 115 patients by Kim, S, Meurisse, A, Stouvenot, M, Jary, M, Hon, T Nguyen Tan, Francois, E, Buecher, B, Andre, T, Samalin, E, Boulbair, F, Bari, B De, Almotlak, H, Klajer, E, Calcagno, F, Chatillon, E, Spehner, L, Jacquin, M, Vendrely, V, Vernerey, D, Borg, C

“…Abstract Background The addition of docetaxel to cisplatin and 5FU (DCF) has shown a promising efficacy in Epitopes-HPV01 study with 4 of first 8 consecutive…”
Get full text

1356PThe level of circulating NKp46+ CD56dim CD16+ natural killer cells predicts distinct survival in non-small cell lung cancer by Picard, E, Godet, Y, Laheurte, C, Boullerot, L, Lauret Marie Joseph, E, Jacquin, M, Kaulek, V, Eberst, G, Gaugler, B, Jacoulet, P, Gainet-Brun, M, Lahoucarde, J, Almotlak, H, Le Pimpec-Barthes, F, Fabre-Guillevin, E, Borg, C, Westeel, V, Adotevi, O

Get full text

Surf: Open label, randomized multi-centre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma (mRCC) by Mouillet, G., Maurina, T., Paillard, M.-J., Montcuquet, P., Hon, T. Nguyen Tan, Almotlak, H., Stein, U., Berthod, D., Robert, E., Meurisse, A., Bonnetain, F., Thiery-Vuillemin, A.

Get full text

Real-life study of BRCA genetic screening in metastatic breast cancer by Meynard, G., Villanueva, C., Thiery-Vuillemin, A., Mansi, L., Montcuquet, P., Meneveau, N., Chaigneau, L., Bazan, F., Almotlak, H., Dobi, E., Nguyen Tan Hon, T., Klajer, E., Fagnoni-Legat, C., Paget-Bailly, S., Meurisse, A., Collonge-Rame, M-A., Populaire-Ventron, C., Pivot, X., Curtit, E.

Get full text

Non Pegylated Liposomal Doxorubicin Beyond the First Line Treatment of Metastatic Breast Cancer Patients: A Retrospective Analysis by Bernhard, S., Mansi, L., Nerich, V., Villanueva, C.B., Dobi, E., Almotlak, H., Bazan, F., Chaigneau, L., Cals, L., Pivot, X.

Get full text

Cancer du sein métastatique surexprimant HER2 : évolutions des thérapeutiques by Pivot, X., Jary, M., Dobi, E., Bazan, F., Chaigneau, L., Cals, L., Almotlak, H., Montcuquet, P., Meneveau, N., Villanueva, C.

“…Currently, the standard first-line treatment for patients with HER2 overexpression in metastatic breast cancer is trastuzumab in combination with taxane. Where…”
Get full text

Cancer du sein métastatique surexprimant HER2: évolutions des thérapeutiques : 10e Biennale monégasque de cancérologie by PIVOT, X, JARY, M, DOBI, E, BAZAN, F, CHAIGNEAU, L, CALS, L, ALMOTLAK, H, MONTCUQUET, P, MENEVEAU, N, VILLANUEVA, C

Get full text